P8 Objective Cough Frequency Monitoring In Bronchiectasis

Spinou, Arietta; Garrod, Rachel; Lee, KK; Elston, Caroline; Loebinger,; Chung, KF; Wilson, Robert; Birring, SS

doi:10.1136/thoraxjnl-2014-206260.158

Cited by 14 publications

(37 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The visual analogue scale (VAS) score was assessed by patients to evaluate treatment response. The VAS employs a linear scoring method with a straight line with calibration of 0, 1, 2-10 cm (scale lines marked from 0 to 100 mm can also be used); 0 indicates asymptomatic, and 10 represents the most serious (Spinou and Birring, 2014). Treatment response was defined as a decrease of ≥50% in the average VAS score.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of noscapine-licorice combination effects on cough relieving in COVID-19 outpatients: A randomized controlled trial

Barati

Feizabadi²,

Khalaj³

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

Background: As February 2023, SARS-CoV-2 is still infecting people and children worldwide. Cough and dyspnea are annoying symptoms almost present in a large proportion of COVID-19 outpatients, and the duration of these symptoms might be long enough to affect the patients’ quality of life. Studies have shown positive effects for noscapine plus licorice in the previous COVID-19 trials. This study aimed to assess the effects of the combination of noscapine and licorice-for relieving cough in outpatients with COVID-19.Methods: This randomized controlled trial was conducted on 124 patients at the Dr. Masih Daneshvari Hospital. Participants over 18 years of age with confirmed COVID-19 and cough were allowed to enter the study if the onset of symptoms was less than 5 days. The primary outcome was to assess the response to treatment over 5 days using the visual analogue scale. Secondary outcomes included the assessment of cough severity after 5 days using Cough Symptom Score, as well as the cough-related quality of life and dyspnea relieving. Patients in the noscapine plus licorice group received Noscough® syrup 20 mL every 6 h for 5 days. The control group received diphenhydramine elixir 7 mL every 8 h.Results: By day five, 53 (85.48%) patients in the Noscough® group and 49 (79.03%) patients in the diphenhydramine group had response to treatment. This difference was not statistically significant (p-value = 0.34). The presence of dyspnea was significantly lower in the Noscough® group versus diphenhydramine at day five (1.61% in the Noscough® group vs. 12.9% in the diphenhydramine group; p-value = 0.03). The cough-related quality of life and severity also significantly favored Noscough® syrup (p-values <0.001).Conclusion: Noscapine plus licorice syrup was slightly superior to diphenhydramine in relieving cough symptoms and dyspnea in the COVID-19 outpatients. The severity of cough and cough-related quality of life were also significantly better in the noscapine plus licorice syrup. Noscapine plus licorice may be a valuable treatment in relieving cough in COVID-19 outpatients.

show abstract

Section: Discussionmentioning

confidence: 99%

Evaluation of noscapine-licorice combination effects on cough relieving in COVID-19 outpatients: A randomized controlled trial

Barati

Feizabadi²,

Khalaj³

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…The advantages and disadvantages of these algorithms cannot be determined because the results of different experiments are different [34,64]. However, MFCCs + SVM is used more widely [65,66], and the neural network has potential to model and achieve accurate identification [67,68].…”

Section: Convolutional Neural Network (Cnn)mentioning

confidence: 99%

Theory and Application of Audio-Based Assessment of Cough

et al. 2018

View full text Add to dashboard Cite

Cough is a common symptom of many respiratory diseases. Many medical literatures underline that a system for the automatic, objective, and reliable detection of cough events is important and very promising to detect pathology severity in chronic cough disease. In order to track the development status of an audio-based cough monitoring system, we briefly described the history of objective cough detection and then illustrated the cough sound generating principle. The probable endpoints of cough clinical studies, including cough frequency, intensity of coughing, and acoustic properties of cough sound, were analyzed in this paper. Finally, we introduce some successful cough monitoring equipment and their recognition algorithm in detail. It can be obtained that, firstly, acoustic variability of cough sounds within and between individuals makes it difficult to assess the intensity of coughing. Furthermore, now great progress in audio-based cough detection is being made. Moreover, accurate portable objective monitoring systems will be available and widely used in home care and clinical trials in the near future.

show abstract

“…6,8,16 Several complementary clinical outcome assessments have been used to measure these aspects of burden and to evaluate treatment benefit in patients with chronic cough who have been treated with pharmacologic or nonpharmacologic approaches. 17,18 Objective cough frequency is often used to assess the efficacy of antitussives in clinical trials, but use of cough-monitoring devices in a clinical practice is impractical. 19 Previously validated cough-related patient-reported outcomes (PROs) include the Leicester Cough Questionnaire (LCQ), 20 Cough-Specific Quality-of-Life Questionnaire, 21 and Cough Severity Diary (CSD), 22,23 all of which can also be used to monitor patients' responses to treatment.…”

Section: Introductionmentioning

confidence: 99%

Validation of a visual analog scale for assessing cough severity in patients with chronic cough

Nguyen

Bacci

Vernon

et al. 2021

Ther Adv Respir Dis

View full text Add to dashboard Cite

Introduction: Patients with chronic cough experience considerable burden. The cough severity visual analog scale (VAS) records patients’ assessment of cough severity on a 100-mm linear scale ranging from “no cough” (0 mm) to “worst cough” (100 mm). Although cough severity scales are widely used in clinical practice and research, their use in patients with refractory or unexplained chronic cough has not been formally validated. Methods: This analysis includes data from a phase 2b randomized controlled trial of the P2X3-receptor antagonist gefapixant for treatment of refractory or unexplained chronic cough (NCT02612610). Cough severity VAS scores were assessed at baseline and Weeks 4, 8, and 12. The cough severity VAS was validated using several outcomes, including the Cough Severity Diary (CSD), Leicester Cough Questionnaire (LCQ), patient global impression of change (PGIC) scale, and objective cough frequency. Validation metrics included test–retest reliability, convergent and known-groups validity, responsiveness, and score interpretation (i.e., clinically meaningful change threshold). Results: The analysis included 253 patients (median age, 61.0 years; females, 76%). Test–retest reliability of the cough severity VAS was moderate (intraclass correlation coefficient, 0.51). The cough severity VAS had acceptable convergent validity with other related measures (Pearson r of 0.53 and -0.41 for CSD and LCQ total scores, respectively; p < 0.0001 for each). Known-groups validity was supported by significant differences in mean cough severity VAS scores across severity groups defined using CSD, LCQ, and cough frequency tertiles. A large effect size was observed in patients with the greatest improvements in PGIC (Cohen d = -1.8). A ⩾ 30-mm reduction in the cough severity VAS was estimated as a clinically meaningful change threshold for clinical trials in chronic cough. Conclusions: The cough severity VAS is a valid and responsive measure. A cough severity VAS reduction of ⩾ 30 mm can discriminate clinically meaningful changes in chronic cough severity in clinical studies.

show abstract

P8 Objective Cough Frequency Monitoring In Bronchiectasis

Cited by 14 publications

References 2 publications

Evaluation of noscapine-licorice combination effects on cough relieving in COVID-19 outpatients: A randomized controlled trial

Evaluation of noscapine-licorice combination effects on cough relieving in COVID-19 outpatients: A randomized controlled trial

Theory and Application of Audio-Based Assessment of Cough

Validation of a visual analog scale for assessing cough severity in patients with chronic cough

Contact Info

Product

Resources

About